πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11266746

Therapeutic antitumor combination of a TLR4 ligand with other treatments

The United Slates of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11260050

Combination of cotinine plus antioxidant for treatment-resistant depression and correction

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11253591

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11246950

Combination cancer immunotherapy with pentaaza macrocyclic ring complex

Galera Labs, LLC Β· Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11234932

Combination HIV therapeutic

Aphios Corporation Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11236139

Combination immunotherapy

The United States Government represented by the Department of Veterans Affairs Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11219608

Triple combination formulation for treatment of chronic pain

Northwestern University Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11219614

Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

Galera Labs, LLC Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11207322

Method and composition related to combination therapy for addiction

The Board of Regents of the University of Texas System Β· Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202784

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11197932

Polymer-drug conjugates for combination anticancer therapy

The Regents of the University of California Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11197844

Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancre

The Regents of the University of California Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191757

Combination of pimavanserin and cytochrome P450 modulators

ACADIA Pharmaceuticals Inc. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11186873

Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (I

Wellmarker Bio Co., LTD. Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11179394

Method for treating cancer using a combination of Chk1 and ATR inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11166963

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11149253

Small molecule compound combination for reprogramming digestive tract derived epithelial c

INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA Β· Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11135225

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. Β· Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11129823

Combination treatment of ocular inflammatory disorders and diseases

Aldeyra Therapeutics, Inc. Β· Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11116838

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

Inovio Pharmaceuticals, Inc. Β· Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11110108

Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitor

Vertex Pharmaceuticals Incorporated Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11110086

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

Vertex Pharmaceuticals Incorporated Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11110099

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11103504

Combination of a DNA condensation-inducing compound and an Eis inhibitor for antibiotic tr

ACADEMISCH MEDISCH CENTRUM Β· Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted